<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637468</url>
  </required_header>
  <id_info>
    <org_study_id>S 020301</org_study_id>
    <nct_id>NCT00637468</nct_id>
  </id_info>
  <brief_title>EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye</brief_title>
  <acronym>EAGLE</acronym>
  <official_title>Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the EAGLE Study is to compare the efficacy of conservative medical treatment and
      local intraarterial fibrinolysis in patients with central retinal artery occlusion and to
      evaluate benefit and risk for the patient of both therapies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to results of conditional power analysis performed at the first interim analysis and due to
    observed spectrum of adverse events.
  </why_stopped>
  <start_date>September 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity 1 month after therapy in comparison with visual acuity before therapy measured according to ETDRS Scale.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of visual field</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on retinal circulation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of therapies and registration of number, form and severity of complications</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of prognostic factors</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Retinal Artery Occlusion</condition>
  <condition>Fibrinolysis</condition>
  <condition>Visual Acuity</condition>
  <condition>Stroke</condition>
  <condition>Hemodilution</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local intra-arterial fibrinolysis (LIF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conservative standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous injection of heparin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous injection of acetazolamide</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local intra-arterial fibrinolysis</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Globe massage</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical use of beta-blocker</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovolaemic haemodilution</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subtotal central retinal artery occlusion or central retinal artery occlusion with
             choroidal hypoperfusion not lasting longer than 20h

          -  Patients aged from 18 years to 75 years (in case of pre-existing blindness of other
             eye also older than 75 years)

          -  Informed consent of the patient

        Exclusion Criteria:

          -  Central retinal artery occlusion lasting longer than 20h

          -  Eye diseases, namely branch retinal artery occlusion, cilioretinal arteries supplying
             the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy and
             elevated intraocular pressure (over 30 mmHg)

          -  Systemic diseases, namely severe general diseases, systemic arterial hypertension
             (systolic pressure &gt; 200 mmHg), despite medical therapy, acute systemic inflammation
             (erythrocyte sedimentation rate &gt; 30 mm within the first hour/ C-reactive protein &gt;
             1,0 mg/dl), antithrombin-III deficiency in case of thrombocytopenia (&lt; 100000 per ml):
             pathologic clotting time, acute pancreatitis with elevated pancreas enzymes

          -  Medical History: heart attack within the last 6 weeks, intracerebral bleeding or
             neurosurgical operation within the last 4 weeks, therapy with marcumar/warfarin,
             allergic reaction to contrast agent, haemorrhagic diathesis, aneurysms, inflammatory
             vascular diseases (e.g., giant cell arteritis, Wegener´s granulomatosis),
             endocarditis, gastric ulcer

          -  Patient participation in other studies during the prior 4 weeks

          -  No willingness and ability of the patient to participate in all follow-up examinations

          -  Pregnancy

          -  Written consent not given

          -  Patient is not mobile (bedridden)

          -  Other conditions/ circumstances likely to lead to poor treatment adherence (e.g.,
             history of poor compliance, alcohol or drug dependency, no fixed abode)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schumacher, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neuroradiology, University Medical Center Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universityhospital Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital of RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKL Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Hamburg Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Homburg/Saar</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität zu Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityhospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Feltgen N, Neubauer A, Jurklies B, Schmoor C, Schmidt D, Wanke J, Maier-Lenz H, Schumacher M; EAGLE-Study Group. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 : EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):950-6. Epub 2005 Dec 22.</citation>
    <PMID>16372192</PMID>
  </reference>
  <reference>
    <citation>Feltgen N, Reinhard T, Kampik A, Jurklies B, Brückmann H, Schumacher M. [Lysis therapy vs. conservative therapy: randomised and prospective study on the treatment of acute central retinal artery occlusion (EAGLE study)]. Ophthalmologe. 2006 Oct;103(10):898-900. German.</citation>
    <PMID>16998653</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>March 17, 2008</last_update_submitted>
  <last_update_submitted_qc>March 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Artery Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

